NEW YORK, March 12 - CuraGen and Alexion Pharmaceuticals on Tuesday said they have signed a deal to discover and validate cancer-related biologic and small-molecule drug targets.

Terms of the multi-year agreement, which may grow in the future to include other diseases, call for CuraGen to apply its functional genomic technologies to help Alexion identify drug targets from data the biotech company will provide.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.